European Primary Care Cardiovascular Society

Fitting in bempedoic acid in the arsenal of lipid-lowering therapies

3' education - Mar. 30, 2023 - Prof. Kausik Ray, MD

Lowering LDL-c and CV risk with new evidence-based non-statin treatment

3' education - Mar. 18, 2023 - Prof. Peter Libby, MD

No association of early eGFR decline after transitioning to ARNI with adverse outcomes

3' education - Mar. 14, 2023 - Safia Chatur, MD

A phase 3 trial with bempedoic acid: Strengths and limitations

3' education - Mar. 13, 2023 - Prof. Eugene Yang, MD

Low-carbohydrate high-fat diet is associated with CV events

3' education - Mar. 11, 2023 - Liam Brunham, MD, PhD

Bempedoic acid in CV outcomes trial in statin-intolerant patients

3' education - Mar. 10, 2023 - Prof. Steven Nissen, MD

Results for oral PCSK9 inhibitor promising to proceed to phase 3 trials

3' education - Mar. 9, 2023 - Prof. Christie Ballantyne, MD

CODE-EHR, a framework for the use of electronic health record data in clinical research

5' education - Oct. 13, 2022 - Prof. Folkert Asselbergs, MD, PhD

Risk of CVD in patients with autoimmune diseases

5' education - Oct. 12, 2022 - Prof. Naveed Sattar, MD, PhD

DOAC versus VKA in rheumatic atrial fibrillation

3' education - Sep. 15, 2022 - Prof. Ganesan Karthikeyan, MD

What are the real effects of statins on muscle symptoms?

3' education - Sep. 12, 2022 - Prof. Colin Baigent, MD

Aspirin or P2Y12i monotherapy for secondary prevention in patients with CAD?

3' education - Sep. 5, 2022 - Prof. Marco Valgimigli, MD, PhD

Long-term use of PCSK9i reduces CV events in ASCVD

3' education - Aug. 29, 2022 - Michelle O'Donoghue, MD

Smartphone-based screening more than doubles detection rate of atrial fibrillation

3' education - Aug. 28, 2022 - Prof. Axel Bauer, MD

A community-based screening trial for CVD

3' education - Aug. 28, 2022 - Prof. Axel Diederichsen, MD

Improved outcomes with SGLT2i in HFpEF and HFmrEF

3' education - Aug. 27, 2022 - Prof. Scott Solomon, MD

Patients with heart failure benefit from SGLT2i regardless of ejection fraction

3' education - Aug. 27, 2022 - Prof. Pardeep Jhund, MD, PhD

ARNI has no negative effect on cognitive function

3' education - Aug. 26, 2022 - Prof. John McMurray, MD

A discussion on CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl

10' education - June 20, 2022 - Prof. Ulrich Laufs, MD, PhD, prof. Chris Packard, PhD and prof. Wouter Jukema, MD, PhD

What are potential mechanisms of benefit of icosapent ethyl?

10' education - June 20, 2022 - Prof. Chris Packard, PhD

Effect of optimal risk factor management on recurrent ASCVD risk

Literature - Apr. 4, 2023 - Van Trier TJ, et al. - Eur J Prev Cardiol. 2023

A pooled analysis of patients with established ASCVD showed a 10-year risk of recurrent ASCVD events of 20% and a lifetime risk of 54%. Theoretically, optimization of both lifestyle and medications could reduce both risks and add 7.3 event-free years.

Fitting in bempedoic acid in the arsenal of lipid-lowering therapies

3' education - Mar. 30, 2023 - Prof. Kausik Ray, MD
“Lowering LDL-c by any means reduces CV events […], but any drug on its own is not going to be enough for high risk patients. We've got to use combination therapies and it’s great to have all these different options, which we can now combine in our patients”, says Prof. Ray.

ACC.23 “Lowering LDL-c by any means reduces CV events […], but any drug on its own is not going to be enough for high risk patients. We've got to use combination therapies and it’s great to have all these different options, which we can now combine in our patients”, says Prof. Ray.

Lowering LDL-c and CV risk with new evidence-based non-statin treatment

3' education - Mar. 18, 2023 - Prof. Peter Libby, MD
Prof. Libby shares his view on the clinical impact of the results of the CLEAR Outcomes trial which investigated the effect of bempedoic acid on CV outcomes.

ACC.23 Prof. Libby shares his view on the clinical impact of the results of the CLEAR Outcomes trial which investigated the effect of bempedoic acid on CV outcomes.

No association of early eGFR decline after transitioning to ARNI with adverse outcomes

3' education - Mar. 14, 2023 - Safia Chatur, MD

ACC.23 "Early treatment-related eGFR decline should not stall uptitration or impede continuation of ARNI", says Safia Chatur. She lists the findings of an analysis of PARADIGM-HF and PARAGON-HF in patients with HF.

Improved use of high-intensity statin with centrally controlled individualized reminders

News - Mar. 14, 2023

ACC.23 In a multisite-RCT study was examined whether an intervention including individualized reminders sent to primary care clinicians improved use of high-intensity statin in patients with ASCVD.

Improved prescription of therapies with multifaceted intervention in T2DM and ASCVD

News - Mar. 14, 2023

ACC.23 In the COORDINATE-Diabetes trial was investigated whether a multifaceted intervention can improve prescription of 3 groups of evidence-based therapies in patients with T2DM and ASCVD.

Association between lifelong endurance exercise and higher coronary plaque burden

News - Mar. 14, 2023
Among men aged 45 to 70 years without CV risk factors, lifelong endurance athletes have a higher coronary plaque burden compared to participants who exercise up to 3 hours per week.

ACC.23 Among men aged 45 to 70 years without CV risk factors, lifelong endurance athletes have a higher coronary plaque burden compared to participants who exercise up to 3 hours per week.

LDL-c lowering with new oral PCSK9 inhibitor in hypercholesterolemia

News - Mar. 14, 2023

ACC.23 Injectable treatments may have poor adoption due to access barriers and the need for repeat injections. An oral PCSK9 inhibitor, MK-0616, was developed and tested in a phase 2b trial.

Association of self-reported keto diet with LDL-c and apoB levels and CV events

News - Mar. 14, 2023

ACC.23 UK Biobank participants who followed a low-carbohydrate high-fat diet had higher LDL-c and apoB levels and an increased risk of incident MACE compared with those on a standard diet.

Likelihood of prescribing MRA increased with EHR alert in HFrEF

News - Mar. 14, 2023

ACC.23 An EHR-embedded and selective alert delivered during the clinical encounter increased the likelihood of prescribing MRA by 2.5x in MRA-eligible HFrEF patients in an outpatient cardiology setting.

Reduction of CV events with bempedoic acid in statin-intolerant patients

News - Mar. 14, 2023

ACC.23 The CLEAR Outcomes study showed that among statin-intolerant primary and secondary prevention patients, bempedoic acid reduced the risk of the primary composite endpoint of nonfatal MI, nonfatal stroke, coronary revascularization or CV death.

A phase 3 trial with bempedoic acid: Strengths and limitations

3' education - Mar. 13, 2023 - Prof. Eugene Yang, MD
Eugene Yang reviews the results of the CLEAR Outcomes trial and talks about the strengths and limitations of the study.

ACC.23 Eugene Yang discusses the results of the CLEAR Outcomes trial and talks about the strengths and limitations of the study.

Agenda